BioSpace News Archive

The only tertiary analysis appliance on the market, CompStor Insight ™ delivers 7x faster annotation in an easy to use solution with integrated workflows, multi-user support, needing no special IT skills

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report third quarter 2020 financial results on Wednesday, November 4, 2020, prior to the open of the market.

Celsius Holdings, Inc., (Nasdaq: CELH), maker of the leading global fitness drink, CELSIUS®, today announced that it will release financial results for the third quarter ended September 30, 2020 on Thursday, November 12, 2020 , before the market open. Management will then host a conference call that same day at 10:00 a.m. Eas

ATAI Life Sciences (“ATAI” or the “Company”), a global biotechnology company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced that Neuronasal Inc. (“Neuronasal”) has completed its pilot study intended to show nose to brain delivery of N-acetylcysteine (NAC) in healthy volunteers.

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will participate as a gold level sponsor at the Society for Minimally Invasive Spine Surgery (SMISS) Annual Forum held virtually from Octo

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the expansion of its leadership team with the appointments of Paolo Manfredi, M.D., as Acting Chief Scientific Officer and Marco Pappagallo, M.D., as Acting Chief Medical Officer.

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter fiscal 2020 conference call on Wednesday, November 4, at 4 p.m. CT (5 p.m. ET).

DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of modeling and simulation software for pharmaceutical safety and efficacy, today announced that simulations using their DILIsym® software were noted in a U.S. Food and Drug Administration (FDA) review of the New Drug Application for Pexidartinib (Turalio®, marketed by Daiichi Sankyo, Inc.)

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced updates for the continued development of its ATI-1701 biodefense vaccine program.

Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has submitted a Pre-IDE filing to the U.S. Food and Drug Administration and has requested a meeting with the FDA to discuss a few key matters in advance of the filing of its IDE application for the VenoValve U.S. pivotal trial.